Chuck has served as President, Chief Executive Officer and Board Member of Mirati Therapeutics since 2012. Under his leadership, Mirati has transformed into a precision oncology company focused on advancing drug discovery and research and delivering novel therapeutics that target the genetic and immunologic drivers of cancer.
Prior to joining Mirati, Chuck was Senior Vice President for Biotherapeutic Clinical Research within Pfizer’s Worldwide Research & Development division. He was at Pfizer from 2003 to 2012, serving in roles of increasing responsibility, including Vice President, Head of Oncology Development and Chief Medical Officer for Pfizer’s Biotherapeutics and Bioinnovation Center. He was responsible for the development of Pfizer’s oncology portfolio, including Inlyta,* Xalkori* and the approval of Sutent.* Prior to Pfizer, Chuck was at Schering-Plough where he was responsible for the Phase I-IV development of several oncology compounds, including Temodar.*
Chuck’s career has also included academic and hospital positions at Stanford and Emory universities. He currently serves as chairman of the board at OncoMyx Therapeutics, board of directors member at BCTG Acquisition Corp and PMV Pharmaceuticals, Inc. and on the Scientific Advisory Board at ALX Oncology. He served as a member of the board of Array Biopharma from 2014 to 2019 when it was acquired by Pfizer, Inc. and Immunomedics from 2019 to 2020 when it was acquired by Gilead.
Chuck received his M.D. and Ph.D. degrees from Washington University School of Medicine and completed his post-graduate training at Stanford University. Additionally, he has received research support from the National Institutes of Health and the American Cancer Society, published more than 50 peer-reviewed manuscripts and holds a number of patents and patent applications.
What is Charles M. Baum's net worth?
The estimated net worth of Charles M. Baum is at least $9.91 million as of January 4th, 2023. Dr. Baum owns 168,777 shares of Mirati Therapeutics stock worth more than $9,907,210 as of November 7th. This net worth evaluation does not reflect any other assets that Dr. Baum may own. Additionally, Dr. Baum receives a salary of $1,070,000.00 as CEO at Mirati Therapeutics. Learn More about Charles M. Baum's net worth.
How old is Charles M. Baum?
Dr. Baum is currently 66 years old. There are 6 older executives and no younger executives at Mirati Therapeutics. The oldest executive at Mirati Therapeutics is Dr. Alan Bart Sandler M.D., Executive VP & Chief Medical Officer, who is 67 years old. Learn More on Charles M. Baum's age.
What is Charles M. Baum's salary?
As the CEO of Mirati Therapeutics, Inc., Dr. Baum earns $1,070,000.00 per year. The highest earning executive at Mirati Therapeutics is Dr. James G. Christensen Ph.D., Executive VP & Chief Scientific Officer, who commands a salary of $1,760,000.00 per year. Learn More on Charles M. Baum's salary.
How do I contact Charles M. Baum?
Has Charles M. Baum been buying or selling shares of Mirati Therapeutics?
Charles M. Baum has not been actively trading shares of Mirati Therapeutics in the last ninety days. Most recently, Charles M. Baum sold 3,648 shares of the business's stock in a transaction on Wednesday, January 4th. The shares were sold at an average price of $46.60, for a transaction totalling $169,996.80. Following the completion of the sale, the insider now directly owns 168,777 shares of the company's stock, valued at $7,865,008.20. Learn More on Charles M. Baum's trading history.
Who are Mirati Therapeutics' active insiders?
Are insiders buying or selling shares of Mirati Therapeutics?
In the last year, insiders at the biotechnology company sold shares 4 times. They sold a total of 7,438 shares worth more than $433,243.25. The most recent insider tranaction occured on January, 16th when EVP Benjamin Hickey sold 1,597 shares worth more than $94,254.94. Insiders at Mirati Therapeutics own 3.3% of the company.
Learn More about insider trades at Mirati Therapeutics. Information on this page was last updated on 1/16/2024.
